安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- RTW INVESTMENTS, LP Schedule 13G Filing Concerning AQST on 2025-09-30 . . .
This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0 001 per share (the "Shares") of Aquestive Therapeutics, Inc (the "Company") directly held by the RTW Funds; and (ii) Roder
- Aquestive Therapeutics Announces $75M Strategic Funding
As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building and supporting the companies and or academics developing them
- RTW Biotech Lands $75M Financing Deal with Aquestive
RTW Biotech Opportunities has signed a $75 million financing deal with Aquestive The Guernsey-based biotech firm focuses on transformative assets with high growth potential in biopharmaceuticals and medical technology
- Aquestive Therapeutics Shares Rise After $75 Million Funding Deal - MSN
Aquestive Therapeutics Inc (NASDAQ:AQST) stock climbed 5 7% following the announcement of a $75 million strategic funding agreement with RTW Investments, LP, contingent on FDA approval of its
- Aquestive Therapeutics announces $75M strategic funding agreement with RTW
Aquestive Therapeutics (AQST) announced a $75M strategic funding agreement with funds managed by RTW Investments, subject to United States FDA approval of Anaphylm Sublingual Film and other conditions
- Biotech Firm Aquestive Secures $75M Backing for Oral Anaphylaxis . . .
Aquestive Therapeutics (NASDAQ: AQST) has secured a $75 million strategic funding agreement with RTW Investments to support the potential launch of Anaphylm™, a sublingual film for emergency treatment of allergic reactions The funding is contingent on FDA approval and other conditions
- Aquestive Therapeutics Announces $75M Strategic Funding Agreemen
Aquestive Therapeutics (AQST) has announced a $75 million strategic funding agreement with RTW Investments to support the potential market launch of Anaphylm™, a sublingual film intended for the emergency treatment of severe allergic reactions, including anaphylaxis
- Aquestive secures $75 million funding from RTW for Anaphylm launch
Aquestive Therapeutics Inc (NASDAQ: AQST) announced a $75 million strategic funding agreement with RTW Investments LP to support the potential commercial launch of Anaphylm, its epinephrine
|
|
|